Production and Application of 123I-Labeled M-Iodobenzylguanidine (123I-MIBG)

  • Lee C. Washburn
  • Ramesh C. Khosla
  • Craig C. Williams
  • Michael J. Gelfand
  • Harry R. MaxonIII

Abstract

131I-Labeled m-iodobenzylguanidine (131I-mIBG) was first synthesized by Wieland and co-workers1 and soon became widely used for diagnosis of neural crest tumors, such as pheochromocytoma2 and neuroblastoma.3 Because of I-123’s superior physical properties for scintigraphic imaging compared to I-131,4 123I-mIBG has become the preferred agent for diagnosis, staging, and clinical follow-up of patients with these tumors. In addition, 123I-mIBG has shown potential for cardiac applications, such as determination of regional myocardial adrenergic activity following myocardial infarctions5 and prioritization of candidates for heart transplantation.6

Keywords

Radiochemical Purity Radiochemical Yield Radionuclidic Purity Empty Vial Cardiac Application 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wieland, D.M., Wu, J.-I., Brown, L.E., Mangner, T.J., Swanson, D.P., and Beierwaltes, W.H. Radiolabeled adrenergic neuron-blocking agents: Adrenomedullary imaging with [131I]iodobenzylguanidine. J. Nucl. Med. 21:349–353(1980).PubMedGoogle Scholar
  2. 2.
    Shapiro, B., Copp, J.E., Sisson, J.C., Eyre, P.L., Wallis, J., and Beierwaltes, W.H. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytomas: Experience in 400 cases. J. Nucl. Med. 26: 576–585 (1985).PubMedGoogle Scholar
  3. 3.
    Munkner, T. 131I-Meta-iodobenzylguanidine scintigraphy of neuroblastomas. Semin. Nucl. Med. 15:154–160(1985).PubMedCrossRefGoogle Scholar
  4. 4.
    Home, T., Hawkins, L.A., Britton, K.E., Granowska, M., Bouloux, P. and Besser, G. M. Imaging of phaeochromocytoma and adrenal medulla with 123I-meta-iodobenzyl guanidine. Nucl. Med. Commun. 5:763–768 (1984).CrossRefGoogle Scholar
  5. 5.
    McGhie, A.I., Corbett, J.R., Akers, M.S., Kulkarni, P., Sills, M.N., Kremers, M., Buja, L.M., Durant-Reville, M., Parkey, R.W., and Willerson, J.T. Regional cardiac adrenergic function using 1–123 meta-iodobenzylguanidine tomographic imaging after acute myocardial infarction. A.M. J. Cardiol. 67:236–242 (1991).CrossRefGoogle Scholar
  6. 6.
    Merlet, P., Valette, H., Dubois-Randè, J.-L., Moyse, D., Duboc, D., Dove, P., Bourguignon, M.H., Benvenuti, C., Duval, A.M., Agostini, D., Loisance, D., Castaigne, A., and Syrota, A. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J. Nucl. Med. 33:471–477 (1992).PubMedGoogle Scholar
  7. 7.
    Paltiel, H.J., Gelfand, M.J., Elgazzar, A.H., Washburn, L.C., Harris, R.E., Masters, P.R., and Golsch, G.J. 1–123 MIBG imaging of neural crest tumors in children. Radiology (submitted).Google Scholar
  8. 8.
    Gelfand, M.J., Paltiel, HJ., Elgazzar, A.H., Washburn, L.C., Williams, C.C., Harris, R.E., Masters, P.R., and Maxon, H.R. I-123-MIBG imaging of neural crest tumors. J. Nucl. Med. 33:1072 (1992) (abstract).Google Scholar
  9. 9.
    Mock, B.H. and Weiner, R.E. Simplified solid-state labeling of [123I]m-iodobenzyl-guanidine. Appl. Radiat. Isot. 39:939–942 (1988).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Lee C. Washburn
    • 1
  • Ramesh C. Khosla
    • 1
  • Craig C. Williams
    • 1
  • Michael J. Gelfand
    • 1
    • 2
  • Harry R. MaxonIII
    • 1
  1. 1.University of Cincinnati Medical CenterCincinnatiUSA
  2. 2.Children’s Hospital Medical CenterCincinnatiUSA

Personalised recommendations